Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Provectus Granted China Patent for Imaging Drug

publication date: Feb 27, 2008

Provectus Pharmaceuticals, Inc. was granted patents in China and Europe for the use of PV-10 as an imaging agent for CT and MRI scans. PV-10, which is commonly known as Rose Bengal, was given the patent as an imaging agent for diagnosis of cancer. However, the use of PV-10 as an imaging agent is less important to Provectus than use of the drug as a treatment for cancer and dermatological conditions. Clinical trials for both indications are in progress. More details...


Stock Symbol: (OTCBB: PVCT)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital